Dicyclomine Hydrochloride Capsules, 10mg recall — Aurobindo Pharma Usa Inc (Class II)
Aurobindo Pharma Usa Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Dicyclomine Hydrochloride Capsules, 10mg — a Class II recall, initiated 2026-07-23 and posted to the FDA enforcement report on 2026-08-12, under recall number D-0733-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “shortfill; reports of empty capsules.”. From the product description, the form is capsules, the strength given is 10mg, the package is described as 1,000 bottles and it is marked Rx only. 1 National Drug Code number is printed in the record: 59651-719-99. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99492. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.
Regulatory snapshot
| Recall number | D-0733-2026 |
|---|---|
| FDA event ID | 99492 |
| Classification | Class II (intermediate regulatory tier) |
| Status | Ongoing |
| Recalling firm | Aurobindo Pharma Usa Inc |
| Recall initiated | 2026-07-23 |
| Reported by FDA | 2026-08-12 |
| Report lag | 20 days from initiation to report |
| Distribution | US Nationwide. — Nationwide (US) |
| Firm location on record | NJ, United States |
| Product description (source) | Dicyclomine Hydrochloride Capsules, USP, 10mg, 1,000 bottles, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-719-99 |
Reason reported by FDA
shortfill; reports of empty capsules.
5 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.
Product identifiers in this record
7 identifying values matched by exact pattern in the 27-word product description above; each is a literal substring of it.
| Product named | Dicyclomine Hydrochloride Capsules |
|---|---|
| Form | Capsules |
| Strength | 10mg |
| Package | 1,000 bottles |
| NDC | 59651-719-99 |
| Marketing category | Rx only |
| Stated origin | India |
| Distributed by | Aurobindo Pharma USA, Inc. |
Reported in the same month (2026-08)
11 enforcement reports carry a report date in 2026-08; these 4 are the Class II ones nearest this record.
| Recall record | Recall number | Recalling firm | FDA tier | Reported |
|---|---|---|---|---|
| Mirabegron Extended-Release Tablets, 25 mg | D-0745-2026 | Zydus Pharmaceuticals (usa) Inc | Class II | 2026-08-12 |
| Dorzolamide HCl and Timolol Maleate Ophthalmic Solution, 2%/0.5% | D-0730-2026 | Micro Labs Usa Inc | Class II | 2026-08-05 |
| Azelaic Acid Gel, 15% | D-0731-2026 | Glenmark Pharmaceuticals Inc., Usa | Class II | 2026-08-05 |
| Mycophenolate Mofetil for Injection USP, 500 mg/Vial | D-0734-2026 | Mylan Pharmaceuticals Inc | Class II | 2026-08-05 |
Nearest Class II recalls by date
213 of 250 indexed records share the Class II tier; the 10 nearest to 2026-08-12 by report date are listed here.
| Recall record | Recall number | Recalling firm | Strength / form | Reported |
|---|---|---|---|---|
| Levothyroxine Sodium Tablets, 25 mcg | D-0700-2026 | Major Pharmaceuticals | 25 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 50 mcg | D-0701-2026 | Major Pharmaceuticals | 50 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0702-2026 | Major Pharmaceuticals | 75 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 88 mcg | D-0703-2026 | Major Pharmaceuticals | 88 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 112 mcg | D-0704-2026 | Major Pharmaceuticals | 112 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 125 mcg | D-0705-2026 | Major Pharmaceuticals | 125 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 150 mcg | D-0706-2026 | Major Pharmaceuticals | 150 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 25 mcg | D-0707-2026 | Major Pharmaceuticals | 25 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 50 mcg | D-0708-2026 | Major Pharmaceuticals | 50 mcg · Tablets | 2026-07-29 |
| Levothyroxine Sodium Tablets, 75 mcg | D-0709-2026 | Major Pharmaceuticals | 75 mcg · Tablets | 2026-07-29 |
Reading this record
Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 59651-719-99 at the FDA source to confirm it is covered.
Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Aurobindo Pharma Usa Inc (1 indexed records) aggregates this firm across datasets.
Coverage and limits of this record
This page reflects the openFDA enforcement report for D-0733-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.
Source & provenance
- Official source
- https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0733-2026%22
- Source dataset
- openFDA Drug Enforcement API
- Publication date
- 2026-08-12
- Ingested
- 2026-08-22
- Record hash
859acb0fd5aa4b77
Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.